<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Reijs, A.E.M.</title>
    <link>http://repub.eur.nl/res/aut/9153/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Brain perfusion patterns in familial frontotemporal lobar degeneration (Article)</title>
      <link>http://repub.eur.nl/res/pub/31214/</link>
      <pubDate>2011-07-26T00:00:00Z</pubDate>
      <description>Objective: Frontotemporal lobar degeneration (FTLD) is a clinically, genetically, and pathologically heterogeneous disorder. The aim of this study was to compare clinical features and perfusion patterns on SPECT of patients with familial FTLD-TAR DNA binding protein 43 kDa (TDP) and MAPT mutations. Methods: Patients were included if they had MAPT or GRN mutations, positive family history with pathologically proven FTLD in the patient or first-degree relative, or were part of FTD-MND families. All patients and 10 age- and gender-matched controls underwent measurement of brain perfusion using99mTc-HMPAO SPECT. We used SPM8 to perform image processing and oxelbased group analyses (p &lt; 0.001). Gender and age were included as nuisance variables in the design matrices. Results: Of the 29 patients with familial FTLD, 19 had familial FTLD-TDP (GRN mutations in 6), and 10 had MAPT mutations. At clinical presentation, familial FTLD-TDP patients were older at onset (p = 0.030) and had more memory deficits (p &lt; 0.011), whereas patients with MAPT had more naming deficits (p = 0.001) and obsessive-compulsive behavior (p = 0.001). The betweengroups SPECT analyses revealed significantly less perfusion in the right frontal lobe, precuneus, cuneus, and inferior parietal lobule in familial FTLD-TDP, whereas significantly less perfusion was found in the left temporal and inferior frontal gyri in MAPT. Post hoc analysis of familial FTLD-TDP with unknown genetic defect vs MAPT revealed less perfusion in the right frontal and parietal lobe. Conclusion: Familial FTLD-TDP shows relatively more posterior hypoperfusion, including the precuneus and inferior parietal lobule, possibly related to significant memory impairment. Patients with MAPT were characterized by impaired perfusion of the temporal regions and naming deficits. </description>
    </item> <item>
      <title>Safety, hemodynamic profile, and feasibility of dobutamine stress technetium myocardial perfusion single-photon emission CT imaging for evaluation of coronary artery disease in the elderly (Article)</title>
      <link>http://repub.eur.nl/res/pub/9286/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>OBJECTIVES: Cardiovascular disease is the leading cause of morbidity and
          mortality in the elderly. The evaluation of coronary artery disease by
          exercise stress testing is frequently limited by the patient's inability
          to exercise. Although pharmacologic stress testing with dobutamine is an
          alternative, the safety of dobutamine myocardial perfusion scintigraphy in
          the elderly has not been previously studied. PATIENTS AND METHODS: We
          studied the safety and feasibility of dobutamine (up to 40
          microg/kg/min)-atropine (up to 1 mg) stress myocardial perfusion
          scintigraphy using technetium single-photon emission CT imaging in 227
          patients &gt; or = 70 years old (mean +/- SD age, 75 +/- 4 years). A control
          group of 227 patients &lt; 70 years old (mean age, 55 +/- 11 years; matched
          for gender, prevalence of previous infarction, beta-blocker therapy, and
          severity of resting perfusion abnormalities) was studied to assess
          age-related differences in the safety and the hemodynamic response. A
          feasible test was defined as the achievement of the target heart rate
          and/or an ischemic end point (angina, ST-segment depression, or reversible
          perfusion abnormalities). RESULTS: No myocardial infarction or death
          occurred during the test. The target heart rate was achieved more
          frequently in the elderly patients (87% vs 79%; p &lt; 0.05). The elderly
          patients had a higher prevalence of supraventricular tachycardia (7% vs
          1%; p &lt; 0.005) and premature ventricular contraction (74% vs 32%; p &lt;
          0.005) during the test, as compared to the younger patients. There was a
          trend to a higher prevalence of ventricular tachycardia (5% vs 2%) and
          atrial fibrillation (3% vs 0.4%) in the elderly patients. Arrhythmias were
          terminated spontaneously by termination of dobutamine infusion or by
          administration of metoprolol. Independent predictors of supraventricular
          tachyarrhythmias and ventricular tachycardia were older age (p &lt; 0.001;
          chi(2), 9.8) and myocardial perfusion defect score at rest (p &lt; 0.01;
          chi(2), 6.8) respectively, by using a multivariate analysis of clinical
          and stress test variables. Elderly patients had a higher prevalence of
          systolic BP drop &gt; 20 mm Hg during the test (37% vs 12%; p &lt; 0.05). The
          test was terminated due to hypotension in 2% of the elderly patients and
          in 1% of the control group. Age was the most powerful predictor of
          hypotension (p &lt; 0.005; chi(2), 10.3). The test was considered feasible in
          216 elderly patients (95%) and in 209 patients of the control group (92%).
          CONCLUSION: Dobutamine-atropine stress myocardial perfusion scintigraphy
          is a highly feasible method for the evaluation of coronary artery disease
          in the elderly. Elderly patients have a higher risk for developing
          hypotension and supraventricular tachyarrhythmias during a dobutamine
          stress test. However, dobutamine-induced hypotension is often asymptomatic
          and rarely necessitates the termination of the test.</description>
    </item> <item>
      <title>Site-Specific Intracoronary Heparin Delivery in Humans After Balloon Angioplasty (Article)</title>
      <link>http://repub.eur.nl/res/pub/4988/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>Background Demonstration and quantification of site-specific intracoronary administration of compounds has been confined thus far to the experimental animal laboratory. The aim of this study was to describe a scintigraphic method to demonstrate site-specific intracoronary drug delivery in humans. The methods allow on-line visualization and off-line quantification of site-specifically infused -emitting compounds.

Methods and Results In 12 patients after balloon angioplasty, 99mTc-labeled heparin was administered at the site of dilatation by use of a coil balloon. Both the infusion period and the washout period after the end of infusion were monitored with a -camera. A curve of counts per pixel as a function of time was derived that showed an accumulation phase during infusion followed by a washout phase after the end of infusion. Both phases were fitted by regression analysis and showed a linear accumulation pattern and a biexponential washout pattern. After correction for background counts, 99mTc decay, and body attenuation, peak heparin amount and regional bioavailability were calculated. Peak amount was defined as the initial point of the slow washout component of the biexponential curve (elimination component), and regional bioavailability was defined as the area under the curve of accumulation and washout phase. Half-life and retention time, defined as seven half-lives, were obtained by use of the elimination component after correction for 99mTc decay. Mean peak delivered amount was 45±44 IU (236±228 µg), corresponding to an efficiency of delivery ranging from 1% to 8% of the totally infused dose. Total regionally bioavailable heparin reached 244±194 IU·h (1.28±1.01 mg·h). Retention time varied from 12 to 90 hours (mean, 50:33±22:50 hours:minutes).

Conclusions Site-specific intracoronary heparin delivery after angioplasty by means of the coil balloon was demonstrated in humans, and regional pharmacokinetics was quantified by use of a radioisotopic technique.</description>
    </item>
  </channel>
</rss>